Yirui Pharma
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing novel small molecule drugs for oncology and immunology.
OncologyImmunology
Technology Platform
A proprietary small molecule discovery platform utilizing structure-based design and high-throughput screening to target oncology and immunology pathways.
Opportunities
Significant market demand in China for novel, targeted cancer and autoimmune therapies presents a major growth opportunity.
Risk Factors
Clinical trial failure of its lead assets represents the most critical near-term risk to the company's valuation and viability.
Competitive Landscape
Faces intense competition from global pharma giants and a crowded field of innovative domestic Chinese biotechs in oncology and immunology.